Barclays
SWTX

Barclays’s SpringWorks Therapeutics SWTX Stock Holding History

Barclays’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,632,615
Closed -$76.7M – 5723
2025
Q2 		$76.7M Buy
1,632,615
+703,796
+76% +$31.3M 0.02% 562
2025
Q1 		$41M Buy
928,819
+772,696
+495% +$35.6M 0.01% 727
2024
Q4 		$5.64M Buy
156,123
+447
+0.3% +$15.6K ﹤0.01% 2041
2024
Q3 		$4.99M Buy
155,676
+58,645
+60% +$2.19M ﹤0.01% 2099
2024
Q2 		$3.66M Buy
97,031
+24,252
+33% +$1.02M ﹤0.01% 1728
2024
Q1 		$3.58M Sell
72,779
-81,494
-53% -$3.77M ﹤0.01% 2077
2023
Q4 		$5.63M Buy
154,273
+56,357
+58% +$1.47M ﹤0.01% 1988
2023
Q3 		$2.26M Sell
97,916
-23,844
-20% -$652K ﹤0.01% 1821
2023
Q2 		$3.19M Sell
121,760
-536,105
-81% -$14.1M ﹤0.01% 1607
2023
Q1 		$16.9M Sell
657,865
-317,947
-33% -$9.29M 0.01% 913
2022
Q4 		$25.4M Buy
975,812
+823,439
+540% +$20.3M 0.01% 782
2022
Q3 		$4.35M Buy
152,373
+139,337
+1,069% +$3.99M ﹤0.01% 1250
2022
Q2 		$321K Sell
13,036
-13,896
-52% -$508K ﹤0.01% 3153
2022
Q1 		$1.52M Buy
+26,932
New +$1.54M ﹤0.01% 2082

Other funds holding SWTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Barclays's SWTX Position: Q3 2025 in Review

Barclays sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 1,632,615 shares — an estimated $76.7M sold.

Barclays first reported a position in SWTX in Q1 2022 and held it in 14 quarters. The position peaked at $76.7M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

  • Barclays reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Barclays sold 1,632,615 SpringWorks Therapeutics shares in Q3 2025, an estimated $76.7M.
  • Barclays first reported a position in SpringWorks Therapeutics in Q1 2022 and held it in 14 quarters.
  • Barclays's SpringWorks Therapeutics position peaked at $76.7M in Q2 2025.
  • 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.